Table 3.
Hazard ratio between treatments (romosozumab versus placebo) in the first year of FRAME for various fracture outcomes at different values of 10-year probability (%) of a MOF calculated without BMD. Italicised numbers indicate that the 95% CIs for the effect estimate exclude unity
| Percentile | 10-year probability (%) | Any clinical fracture | Osteoporotic fracture | Major osteoporotic fracture | Nonvertebral fracturea | Morphometric vertebral fracture | Clinical vertebral fracture |
|---|---|---|---|---|---|---|---|
| 10th | 3.65 | 0.81 (0.55–1.20) | 0.88 (0.56–1.40) | 0.96 (0.55–1.68) | 1.00 (0.62–1.61) | 0.25 (0.12–0.52) | 0.14 (0.02–1.10) |
| 25th | 4.70 | 0.78 (0.54–1.13) | 0.84 (0.55–1.30) | 0.91 (0.54–1.54) | 0.95 (0.61–1.49) | 0.26 (0.13–0.51) | 0.15 (0.02–1.04) |
| 50th | 7.38 | 0.71 (0.51–0.97) | 0.76 (0.52–1.10) | 0.80 (0.51–1.27) | 0.84 (0.57–1.24) | 0.26 (0.14–0.48) | 0.17 (0.03–0.93) |
| 75th | 12.23 | 0.59 (0.43–0.81) | 0.62 (0.43–0.89) | 0.64 (0.41–0.99) | 0.67 (0.46–0.98) | 0.27 (0.16–0.47) | 0.21 (0.04–0.98) |
| 90th | 18.88 | 0.46 (0.29–0.73) | 0.47 (0.28–0.79) | 0.47 (0.25–0.87) | 0.49 (0.29–0.84) | 0.29 (0.16–0.52) | 0.29 (0.04–1.93) |
| p value for interaction* | 0.06 | 0.07 | 0.08 | 0.046 | > 0.30 | > 0.30 |
*Two-sided p value for interaction between treatment and FRAX®
aDerived by excluding vertebral fractures from osteoporotic fractures